Early CBD treatment prevented schizophrenia-like symptoms from developing in a rat model | Research

The takeaway

CBD given during the peripubertal period (PND 19-39) prevented the development of social withdrawal, cognitive impairment, and CB1 receptor alterations in a rat model of schizophrenia, while haloperidol did not.

Psychosis prevention researchers, CBD scientists, and clinicians working with high-risk youth.

CBD prevented schizophrenia-like symptoms; haloperidol did not

What the researchers found

Peripubertal CBD treatment (30 mg/kg/day from PND 19-39) reversed social interaction deficits and cognitive impairment in MAM rats. CBD also normalized increased CB1 receptor mRNA and protein expression (and reduced DNA methylation at the CB1 promoter) in the prefrontal cortex. A CB1 antagonist (AM251) partially replicated CBD's effects, but the antipsychotic haloperidol did not.

Why it matters

This suggests that early intervention with CBD during a critical developmental window could prevent schizophrenia-like symptoms from manifesting. The fact that haloperidol (a standard antipsychotic) failed where CBD succeeded highlights CBD's unique mechanism.

The numbers in context

CBD 30 mg/kg/day from PND 19-39. Reversed social interaction and novel object recognition deficits. Normalized CB1 mRNA, protein expression, and DNA methylation in prefrontal cortex. Haloperidol did not produce these effects.

How the study worked

MAM (methylazoxymethanol) model: pregnant rats received MAM at gestational day 17 to produce offspring with schizophrenia-like features. Offspring received CBD (30 mg/kg/day), AM251 (0.5 mg/kg/day), or haloperidol (0.6 mg/kg/day) during the peripubertal period (PND 19-39). Behavioral testing and molecular analysis conducted in adulthood.

What this study cannot tell us

Animal model using a specific prenatal insult that may not replicate all aspects of human schizophrenia. Only one CBD dose tested. The peripubertal treatment window is specific and may not translate directly to human adolescence.

How to read the evidence

Preliminary: single animal study using a specific model, though with compelling behavioral and molecular evidence.

When this study was published

Published in 2019.

The bigger picture

If replicated in humans, this could shift the paradigm for psychosis prevention. Rather than waiting for a first psychotic episode, CBD might prevent it by normalizing the cannabinoid system during a critical developmental window.

Questions still open

Could CBD be used preventively in high-risk adolescents? Is there a human-equivalent treatment window? Would these effects persist long-term without continued CBD treatment? Why did haloperidol fail?

Common questions

Could this work in humans?

The concept is promising but unproven. Human clinical trials would need to identify the right treatment window, appropriate doses, and which at-risk individuals to target. Rat models provide a starting point, not a conclusion.

Why did haloperidol fail when CBD succeeded?

Haloperidol blocks dopamine D2 receptors, while CBD has broader pharmacological actions including modulation of the cannabinoid system, serotonin receptors, and TRPV1 channels. The schizophrenia-like features in this model appeared to be driven by cannabinoid system dysregulation, which haloperidol does not address.

Read the original research

Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia.

Neuropharmacology, 146, 212-221

View on PubMed ↗Publisher’s paper ↗

Citation

Stark, Tibor; Ruda-Kucerova, Jana; Iannotti, Fabio Arturo; D'Addario, Claudio; Di Marco, Roberta; Pekarik, Vladimir; Drazanova, Eva; Piscitelli, Fabiana; Bari, Monica; Babinska, Zuzana; Giurdanella, Giovanni; Di Bartolomeo, Martina; Salomone, Salvatore; Sulcova, Alexandra; Maccarrone, Mauro; Wotjak, Carsten T; Starcuk, Zenon; Drago, Filippo; Mechoulam, Raphael; Di Marzo, Vincenzo; Micale, Vincenzo. (2019). Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia.. Neuropharmacology, 146, 212-221. https://doi.org/10.1016/j.neuropharm.2018.11.035